No Data
No Data
EnVVeno Medical to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, June 27th at 4:00 PM ET IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVN
Market-Moving News for June 21st
SRPT: 45% | Sarepeta Therapeutics shares are trading higher after the company announced FDA approval of an expansion to the labeled indication for ELEVIDYS to include individuals with Duchenne muscula
Express News | EnVVeno Medical Shares Are Trading Higher After the Company Reported Interim Venous Ulcer Healing Data From the SAVVE U.E. Pivotal Trial for VenoValve, Which Will Be Presented at the Society for Vascular Surgery 2024 Annual Meeting
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement From the EnVVeno Medical VenoValve(R) Pivotal Trial to Be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved
New Interim Venous Ulcer Healing Data From the EnVVeno Medical VenoValve(R) Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today ann
Express News | EnVVeno Medical Q1 EPS $(0.31) Beats $(0.40) Estimate